Roche
Roche breast cancer drug Perjeta rejected by NICE
August 6, 2013Sales and Marketing Cancer, NICE, Perjeta, Roche
NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …
Roche allows Valcyte access
August 5, 2013Sales and Marketing HIV, Roche, valcyte
Roche has signed a deal with a United Nations initiative to open up access to an oral drug which is …
Strong growth for Roche in latest results
July 25, 2013Sales and Marketing Alexion, Q2, Rituxan, Roche
Roche has seen strong sales growth in the past six months as it lines up new products to replace its …
New Roche leukaemia drug beats rival
July 24, 2013Research and Development, Sales and Marketing Rituxan, Roche, leukaemia, obinutuzumab
Roche’s next generation leukaemia drug obinutuzumab has beaten the firm’s ageing blood cancer medicine Rituxan in a late-stage trial. The …
NICE ‘no’ for MabThera
July 23, 2013Sales and Marketing MabThera, NHS, NICE, Roche
Roche has been dealt a blow by NICE, with the health watchdog deciding that MabThera should not be used on …
Lucentis and Avastin equal in efficacy
July 19, 2013Research and Development, Sales and Marketing Lucentis, Novartis, Roche, avastin
Latest results released this morning from a UK government trial show that off-label use of Roche’s Avastin is just as …
Roche ‘considers’ Alexion bid
July 16, 2013Research and Development, Sales and Marketing Alexion, Orphan, Roche, soliris
Speculation that Roche is considering a bid for rare disease specialist Alexion Pharmaceuticals has unleashed a flurry of comment – …
Roche’s Erivedge gains conditional EU approval
July 15, 2013Sales and Marketing Curis, EU, Erivedge, Roche, Swiss, Zelboraf
Roche’s cancer pill Erivedge has received a conditional European approval for treatment of the most common type of skin cancer. …
FDA approves Boehringer’s lung cancer drug
July 12, 2013Medical Communications, Sales and Marketing Boehringer, FDA, Roche, Tarceva, afatinib, lung cancer
Boehringer Ingelheim’s late-stage lung cancer drug Gilotrif has received an accelerated FDA approval for patients with a certain genetic mutation. …
Blow for Roche as it halts diabetes drug trial
July 10, 2013Research and Development, Sales and Marketing Roche, aleglitazar, diabetes
Roche has stopped a late-stage trial of its investigational diabetes drug aleglitazar over safety concerns. The move was prompted by …
Roche leukaemia drug granted speedy US review
July 3, 2013Research and Development, Sales and Marketing CLL, FDA, Roche, leukaemia, obinutuzumab
Roche’s investigational leukaemia drug could be available for US patients by the end of the year as the FDA looks …
FDA gives Perjeta priority
July 3, 2013Sales and Marketing FDA, Perjeta, Roche, breast cancer
The FDA has granted priority review status to an application for Roche’s Perjeta to be used before surgery in HER2-positive …
Roche buys blood testing firm for $220m
July 2, 2013Sales and Marketing CMI, Diagnostics, Roche
Roche has acquired Boston-based Constitution Medical Investors in order to buy into its haematology testing system. The cancer drug specialist …
Avastin gets GBM approval
June 18, 2013Research and Development, Sales and Marketing GBM, Roche, avastin
Roche has received a major boost with the first approval in early treatment of the most aggressive form of brain …
Lilly and Roche back US research institute
May 31, 2013Research and Development, Sales and Marketing Roche, lilly, notre dame, research
Eli Lilly and Roche Diagnostics are among the key backers of a $360 million US life sciences research facility which …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
